"I prescribed migraine medications for nineteen years before I realized most of my patients were trapped, not treated."

I am writing this from my kitchen table in Connecticut at 6:47 on a Tuesday morning.

My daughter is upstairs with a migraine that started at 3am.

She's twenty-six.

She's been chronic for four years.

And I am the neurologist who treated her.

What you're about to read may make you angry.

It may make you question things your primary care doctor has said. Things your neurologist has said. Things I said myself for nineteen years to thousands of patients sat across from me in clinic rooms.

I have debated for months whether to write this.

My malpractice insurer would prefer I didn't.

Three colleagues have asked me, gently, to "be careful what I put in writing."

I am writing it anyway.

Because every week I see another patient at the end of the medication carousel — capped on triptans, wearing off Botox three weeks early, constipated on Aimovig, dreading her next appointment — and I cannot in good conscience keep silent about what I have learned these last eighteen months.

If you are reading this, you are probably one of three people:

You are a chronic migraine sufferer who has tried five or six preventives and is wondering if there's anything left.

You are her partner, her mother, her sister — and you've watched her cancel one too many things.

Or you are her doctor, and you have run out of things to prescribe.

This article is for all three of you.

Please read it to the end before you decide what to do.

My credentials, briefly

Twenty-three years a board-certified neurologist. Fifteen of those subspecialized in headache disorders. Hospital practice two days a week, private practice three.

Triptans, beta-blockers, topiramate, amitriptyline, Botox, the CGRP monoclonals — I have prescribed all of them, in their thousands, for nearly two decades.

I was, until eighteen months ago, a textbook neurologist.

I followed the AAN guidelines. I followed the protocols. I went to the conferences. I sat on the panels. I told my patients, with absolute professional confidence, that what I was offering them was the best modern medicine had to offer.

And then my own daughter became chronic.

The night that broke me

It was a Sunday in October last year.

Sophie had been chronic for three years by that point. She had been through topiramate (had to come off it — couldn't find her words at work, she's a first-year associate, she can't be the one losing nouns in client meetings). She had been through propranolol (couldn't climb the stairs to her apartment without pausing). She had been through amitriptyline (twenty pounds in four months, brain fog, gave up). She was on her sixth month of Emgality. The first three months had been brilliant. Months four to six had been steadily worse.

She called me at two-thirty in the morning.

"Mom. It's a bad one. I've taken the rizatriptan. It's not touching it."

I drove from Connecticut to her apartment in Brooklyn at three in the morning.

I let myself in with the spare key.

She was on the bathroom floor between the toilet and the bathtub, in the dark, with a washcloth over her eyes.

She was twenty-five years old and she was on the bathroom floor of her own apartment at three in the morning and there was nothing — nothing — I could give her that her doctor had not already given her, that I had not already prescribed her myself.

I sat on the floor next to her and I held her hand for forty minutes.

She did not speak. She could not.

And somewhere in the middle of those forty minutes, I had the thought I had been pushing away for two years.

The protocol I had spent nineteen years prescribing was failing her. It was failing thousands like her. And I was part of it.

What I started reading at 4am

Sophie went to sleep around five. I drove home as the sun came up. I made coffee. I sat at this same kitchen table.

And I started doing something I had not properly done since my residency years.

I read.

Not the AAN guidelines I already knew. Not the headache society pathway documents I had helped draft input for. Not the pharmaceutical-funded continuing-education modules.

I went into the literature on what was actually happening to my patients on the protocol.

What I found over the following three months changed how I practice medicine.

Botox wear-off. The peer-reviewed data shows up to 62% of chronic migraine patients experience meaningful loss of efficacy in the final two to four weeks of every twelve-week cycle. (PubMed 32797631, PMC10455650.) I had been telling patients this was rare. It is not rare. It is the dominant pattern. The cycles I had been administering on the standard insurance-approved schedule were leaving the majority of my patients underprotected for a quarter of their year.

Triptan tachyphylaxis. Frequent triptan use produces measurable reduction in efficacy. The patients I had been seeing year after year, telling me their sumatriptan "didn't work like it used to" — they weren't catastrophizing. They were describing a documented pharmacodynamic failure. And their primary care doctors were capping them at nine doses a month while their attack frequency stayed at fifteen.

CGRP wear-off and side effects. The class is genuinely a breakthrough. It is also a class with a substantial real-world drop-off pattern at six to nine months and a side-effect profile — constipation, hypertension, hair loss, alopecia, injection-site reactions, fatigue — that the trials understated.

Medication overuse headache. The very drugs we prescribe to abort attacks, taken on more than ten days a month for triptans or fifteen for analgesics, cause more headache. We have built a protocol that, taken to its logical conclusion at high attack frequency, becomes its own disease.

I sat with this for weeks.

The protocol I had built my career on was not failing because my patients were difficult or non-compliant or anxious. It was failing because the protocol itself has structural limits that the specialty has, collectively, declined to confront.

And there was something else I could not stop thinking about. The system that produces this protocol is not designed to find out-of-class solutions. Pharma research budgets fund pharma. Insurance pays for what is in the formulary. Neurologists prescribe what we are trained to prescribe. A non-pharmaceutical, non-prescription, one-time-purchase device that replaces a portion of chronic-migraine treatment is not in anyone's financial interest except the patient's.

And the patient, in this country, is the last person whose interest gets prioritized.

What the data on physical mechanisms is actually showing

Here is what's harder to find unless you go looking for it.

Migraine is not, primarily, a vascular disease anymore. The current understanding — peer-reviewed, accepted across the headache community for the last fifteen years — is that migraine is a neurological event in which the trigeminal nerve and its connected pathways become hypersensitised. The pain you feel in your temple, behind your eye, at the back of your skull — that is the trigeminal and occipital nerve pathways firing pain signals in response to stimuli that wouldn't trouble a non-migrainous nervous system.

Most of the medications I prescribe target the chemistry of that pathway. Triptans constrict blood vessels around the nerve. CGRPs block the receptor that amplifies pain transmission. Botox paralyses the muscle that compresses the nerve.

What I had stopped considering — what almost nobody in my speciality talks about — is the mechanical layer underneath all of that.

The trigeminal and occipital nerves do not float in a vacuum. They run through fascia. They are surrounded by muscle. They sit under skin that gets cold, hot, swollen, stiff. They respond — measurably, predictably, in studies that exist if you look for them — to physical inputs. Compression. Heat. Targeted pressure to specific anatomical points along the pathway.

For thousands of years, sufferers have known this without being told. The peppermint roll-on at the temple. The hot washcloth on the back of the neck. The hand pressed hard against the eyebrow during an attack. The dark room and the cold cloth and the pressure of two fingers at the base of the skull.

What sufferers have been doing instinctively for millennia, the science is now catching up to.

What none of these home methods have got right, in my professional opinion, is the combination.

Heat alone is pleasant but incomplete. The vessels open; the nerve doesn't release.

Compression alone — squeezing a head wrap — gives temporary relief that lifts the moment you take it off.

Electrical stimulation alone, the Cefaly model, works until the nerve adapts to the signal, and then it does not. This is documented across thousands of user reviews — the device that worked beautifully for three to six months, and then stopped.

What the current research suggests — and what eighteen months of looking at my own patients has confirmed — is that the mechanism that doesn't fatigue the nerve, that doesn't lose efficacy at six months, that doesn't require a prescription, and that addresses the pathway physically rather than chemically, is rhythmic air-compression combined with precision heat, targeted at the exact anatomical points along the trigeminal and occipital pathways.

It sounds simple.

That is exactly why my specialty has overlooked it.

We are trained to think in molecules. We are not trained to think in millimeters of mercury.

How I came across the device

A colleague — a resident I trained, now twelve years into her own attending career — emailed me last spring.

"Catherine," she wrote, "I've been seeing some patients use this thing. I don't know what to make of it. The data they're bringing me is — frankly — better than what I'm getting from Aimovig."

She sent me a link.

I was skeptical, of course. We see "miracle migraine devices" in the mail every other month. Most are nonsense. The Aculief clip — a $30 acupressure device — saturated Facebook for two years and converted, by my count, almost no chronic patients in my own clinic.

But she was a former resident, and she does not waste my time, and so I looked.

It was a device called Therakova.

Air compression — calibrated to specific PSI values, delivered in rhythmic pulse cycles, around the head and along the suboccipital region.

Precision heat — held at therapeutic temperature, the same range used in clinical compression therapy.

Targeted to the anatomical points along the trigeminal and occipital nerve pathways — the same points headache specialists palpate during a clinical examination.

I requested one.

I used it on myself for two weeks. I'm not chronic, but I get the occasional migraine — perimenopausal, hormonal, fairly predictable. I caught the next one at the prodrome stage and used the device for the recommended fifteen-minute cycle.

The migraine did not fully establish.

I assumed coincidence. I waited for the next one. Same thing happened.

I gave one to Sophie.

It is the first thing in three years that has consistently broken her attacks at the prodrome stage without a triptan.

I have, in the last fourteen months, recommended it to a number of my private patients and quietly suggested it to hospital patients where I felt I could responsibly do so. The response patterns I have seen, in my own clinical observation, are unlike anything I have seen with a single intervention in nineteen years of practice.

I am aware of how that sentence sounds. I would not have written it eighteen months ago.

What the device actually does, in fifteen minutes

This is the part I want to walk through carefully because it matters.

You sit on a chair. You place the device on your head. You press the button.

For the first five minutes, the heat phase opens the local microcirculation around the trigeminal and occipital nerve pathways. The temperature is held precisely — too cold and you don't open the vessels, too hot and you provoke. The therapeutic window is narrow. The device sits in it.

For the next five minutes, the air-compression phase begins. Rhythmic pulses of pressure delivered around the skull and at the base of the neck. The pressure is not constant — that would do nothing. It rises and falls in a rhythm matched to the venous return cycle, which is what allows the nerve pathway to physically release.

For the final five minutes, the two combine. Heat and rhythmic compression simultaneously, targeted at the anatomical points where the trigeminal nerve branches surface near the skin and where the occipital nerves emerge at the base of the skull.

Fifteen minutes. The device powers off.

You stand up. If you've used it at the prodrome stage — the moment the aura starts, or the first whisper of pain at the temple — there is, in my clinical observation, a meaningful chance the migraine does not progress to a full attack.

If the migraine is already established, the device tends to reduce severity rather than abort. That is honest. I will not tell you it is a triptan. It is not.

What it is — what I have come to believe it is — is the missing physical layer underneath the pharmacological protocol. The mechanism that does not fatigue. The mechanism that does not have a side-effect profile. The mechanism that you can use seventeen days in a row without medication overuse headache. The mechanism that adds to your existing treatment rather than competing with it.

For the right patient — and I think that is most chronic sufferers reading this — it is the thing that gives the protocol back its room to breathe.

What it has cost me to write this

Three things.

A pharmaceutical sales representative whose company I will not name — you can probably guess — has stopped attending our practice meetings since I began discussing this approach with colleagues.

An attending colleague, well known to me, took me aside at a headache conference in Chicago in February and warned me that "talking publicly about this kind of thing puts the specialty in a difficult position."

And the company that makes the device has had three letters from competing manufacturers asking it to substantiate every claim it makes. The company has done so. The letters have continued.

I am not naive about why this article will be unwelcome in certain rooms.

The chronic migraine treatment market in the United States is worth, by conservative estimate, more than fourteen billion dollars per year. CGRP injections alone run hundreds of dollars per patient per month — and out-of-pocket cost when prior authorization is denied can be $700 to $1,200 a month. Botox cycles cost $1,500 to $2,000 every twelve weeks, often only partially covered by insurance. Each chronic migraine patient who finds significant relief through a one-time at-home device represents a loss to that market.

I am not telling you the medications don't work. They do, for many patients, partially.

I am telling you that the protocol has structural failure modes that have been quietly tolerated by my specialty, that pharmaceutical research budgets do not fund non-pharmaceutical solutions, and that there is a physical mechanism most chronic patients have never been offered. After nineteen years of saying nothing, I believe they deserve to be told about it.

What the people who've used it actually say

I asked Therakova for access to their customer testimonial database. I read several hundred of them. The patterns were consistent enough that I'm including a small selection.

These are not unusual. They are typical.

What the offer is, and why I am addressing it directly

The full retail price of the Therakova device, as I understand it, is $200.

That is — and I want to put this in context — significantly less than a single Botox cycle. Less than a month of out-of-pocket CGRP injections when prior auth is denied. Less than two visits to an out-of-network neurologist in most American cities.

A pharmaceutical preventive, with insurance, costs the patient anywhere from $30 to $80 in monthly copay if covered. Without coverage — which happens more often than the specialty wants to admit — the same preventive costs $700 to $1,200 a month, every month, indefinitely.

The Therakova is a one-time purchase.

I have been told the company is currently running a launch offer that brings the price down to $149 for new customers. I do not have a financial interest in whether you buy this. I am not paid by Therakova. I have, on the advice of my legal counsel, declined any commercial relationship with the company specifically so that I can write articles like this one without conflict.

I will say this. If you have spent the last five years on the medication carousel, and you are reading this in the small hours of the morning because your migraine has woken you up again, $149 is — in my professional opinion — the most reasonable thing on offer for you in this category.

The device has a sixty-day money-back guarantee from the manufacturer. If it does not work for you, you return it and receive a full refund. The risk to you of trying it is, in financial terms, your shipping costs and your time.

The risk of not trying it, if you are presently in the position my daughter was in eighteen months ago, is another year on the floor.

The two paths

I want to close with something I find myself saying, increasingly, to patients across the desk at my clinic.

There are two paths in front of you.

The first path is the one you are already on. Another preventive when this one wears off. Another six months on a CGRP that may or may not still be working. Another Botox cycle next quarter, weeks four through twelve good, weeks ten through twelve thinning. Another doctor's appointment to discuss why your triptans are not lasting. Another year of canceled plans, canceled vacations, canceled school plays. Another version of yourself you don't quite recognize looking back at you in the mirror at 6am.

I have walked many patients down this path. It is a real path. It is what we have to offer in the protocol as it currently exists.

The second path is to add — not replace — a physical mechanism to your treatment. To use a fifteen-minute device at the prodrome stage and at the onset of pain, on the days when you feel the storm coming, in the morning when you wake with the aura already started. To give your nervous system the targeted physical input it has been asking for, without any new molecule entering your bloodstream. To find out, over the next sixty days, whether this is the missing layer of your protocol.

The second path costs you $149 and sixty days.

The first path costs you what it has already cost you.

I cannot tell you which is right for you. I can tell you what I tell my own daughter, and what I have told the patients I trust most in my private clinic.

Try this before you accept that the protocol you are on is all there is.

That is the article I would not have written eighteen months ago.

That is the article I would have wanted, eighteen months ago, for Sophie.